SOPHiA GENETICS CSO files initial Form 3
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported his initial ownership on a Form 3.
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported his initial ownership on a Form 3. He directly holds 92,419 ordinary shares, including 30,405 shares issuable upon settlement of five restricted stock unit grants that vest over time with continued service.
He also holds several vested and unvested share options to buy ordinary shares at exercise prices ranging from 3.29 to 18.00, with expiration dates from 2029 through 2035. These option and RSU awards reflect his equity-based compensation and align part of his pay with the company’s share performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (6)
- F1. Includes 30,405 ordinary shares issuable upon settlement of five restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 40 ordinary shares from a March 30, 2022 grant vesting in equal monthly installments through March 30, 2026; (ii) 1,156 ordinary shares from May 18, 2022 grant vesting in equal quarterly installments through May 18, 2026; (iii) 2,640 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iv) 7,279 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (v)19,290 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
- F2. The share options are fully vested and exercisable.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on March 30, 2023, and then in equal monthly installments through March 30, 2026.
- F4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
- F5. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
- F6. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Kevin Puylaert’s Form 3 show for SOPHiA GENETICS (SOPH)?
What restricted stock units (RSUs) are reported for SOPHiA GENETICS CSO Kevin Puylaert?
AI-generated analysis. How Rhea-AI works. Not financial advice.
